¡Ya estamos en ! Descubre más

Alcon

ALC

Capitalización de mercado USD 32 mil M

66.18 USD

-0.40

0.6%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

66.28

+0.10

0.15%

1 día

-0.6%

5 días

2.96%

1 mes

-0.18%

3 meses

-6.29%

6 meses

-16.81%

En lo que va del año

-14.72%

1 año

-12.23%

5 años

-15.46%

10 años

14.02%

Acerca de: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Empleados: 25,942

Atención médica Instrumentos y suministros médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 52.6%

Neutral 36.8%

Negativo 10.5%

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

Zacks Investment Research

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon: A Re-Rating In Eyesight

Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.

Alcon: A Re-Rating In Eyesight

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

Alcon Prices EUR 500 Million Senior Notes Offering

GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.

Alcon Prices EUR 500 Million Senior Notes Offering

Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy

Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.

Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy

Bill Ackman Moves Stocks. These 5 Prove It.

Netflix, Visa and other stocks rose on the news that Bill Ackman was investing in them. The billionaire focuses on buying what he views as high-quality growth companies.

Bill Ackman Moves Stocks. These 5 Prove It.

Bill Ackman once exited Netflix stake in a huff. Why he's buying the streaming giant again as well as these five stocks.

Netflix is once again an apple in Bill Ackman's eye, as the streamer was among six stocks Pershing Square added in the last six months.

Bill Ackman once exited Netflix stake in a huff. Why he's buying the streaming giant again as well as these five stocks.

Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript

Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript

Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs

ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.

Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™